In a phase III trial (NCT00094653), ipilimumab at 3 mg/kg, with or without a gp100 peptide vaccine, significantly improved overall survival (OS) in previously treated advanced melanoma patients compared to the gp100 peptide vaccine alone. The gene discussed is PMEL; the disease is melanoma.